AFP and hepatocellular carcinoma: Tomimaru et al. suggested that the combination of plasma miR-21 and AFP enhanced the performance of AFP in discriminating HCC from healthy volunteers (AUC = 0.971) and patients with chronic hepatitis (AUC = 0.823) [24].